Black Diamond Therapeutics (BDTX) Net Cash Flow (2019 - 2026)

Black Diamond Therapeutics (BDTX) has reported Net Cash Flow for 8 consecutive years, with -$10.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 84.11% year-over-year to -$10.9 million; the trailing twelve-month figure through Jun 2026 stood at -$10.8 million (down 283.17% YoY), and the FY2025 full-year result was -$15.4 million, up 21.99% from the prior year.
• Net Cash Flow retreated to -$10.9 million in Q2 2026 per BDTX's latest filing, from $9.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $62.0 million in Q1 2025 and bottomed at -$68.4 million in Q2 2025.
• Historically, Net Cash Flow has averaged -$2.6 million across 5 years, with a median of -$439500.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow soared 918.0% in 2023, then plunged 1025.7% in 2025.
• Over 5 years, Net Cash Flow stood at -$19.6 million in 2022, then soared by 91.08% to -$1.8 million in 2023, then surged by 841.87% to $13.0 million in 2024, then tumbled by 175.91% to -$9.9 million in 2025, then dropped by 10.16% to -$10.9 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$10.9 million, $9.1 million, and -$9.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.